Listen to Gynecologic Oncology

Editor’s Choice Paper:
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma
Editorial:
What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical College
Gretchen Glaser, MD, Mayo Clinic
John Weroha, MD, Mayo Clinic

Editor’s Choice Paper:
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
Hosted by:
David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology
Featuring:
Amanika Kumar, MD, Mayo Clinic
Laura Havrilesky, MD, Duke University

Editor’s Choice Papers:
Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer
Editorial: Universal testing – Should it be that hard? Probably. If you're doing it right
Hosted by:
Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology
Featuring:
Bhavana Pothuri, MD,NYU Perlmutter Cancer Center
Leigha Senter, MS, CGC, The Ohio State University College of Medicine

TKI Toxicities: A Society of Gynecologic Oncology Podcast
Moderator:
Róisín O’Cearbhaill, MD, Gynecologic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York
Speakers:
BJ Rimel, MD, Gynecologic Oncologist, Cedars-Sinai Medical Center
Erin Crane, MD, MPH, Gynecologic Oncologist, Levine Cancer Institute
Vicky Makker, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center
Jennifer MacDonald, PharmD, Oncology Clinical Pharmacy Specialist, Medical University of South Carolina
Róisín O’Cearbhaill, MD, is joined by BJ Rimel, MD, Erin Crane, MD, MPH, Vicky Makker, MD, and Jennifer McDonald, PharmD, to review the clinical management of tyrosine kinase inhibitors (TKIs) in gynecologic cancers with consideration for dose adjustments and modifications. The speakers discuss the optimal management of commonly encountered toxicities, such as hypertension and hypothyroidism, that are associated with several of the TKIs.
They also highlight management strategies, patient reference materials and anticipatory prescriptions for antihypertensives, antidiarrheals, and antiemetics. The podcast includes two patient cases that delve into information about the differences in toxicities between lenvatinib and pazopanib, hypertension and which drugs to use in which order (both starting dose and dose adjustments), and medical access and lab intervals. These practical clinical pearls in managing toxicities aim to guide practitioners on how best to use these drugs to treat gynecologic cancers.
This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.
Additional Resources: Tyrosine kinase inhibitor toxicities: A Society of Gynecologic Oncology review and recommendations
Download audio
Browse all Gynecologic Oncology audio

Editor’s Choice Papers:
What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women
Editorial: Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approach
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Ann Oluloro, MD, MPH, University of Washington
Eloise Chapman-Davis, MD, Weill Cornell Medicine